← Back to Press Releases May 22, 2026 Safety and efficacy of ETX101, an investigational AAV9-based gene therapy for SCN1A+ Dravet syndrome: Interim results from the POLARIS Phase 1/2 clinical trials Share Post Email Copy Link Cell-Selective Targeting and Regulation The precision gene therapies being developed at Encoded are potentially capable of targeting specific cell types or levels of expression to address a range of disease mechanisms. Learn more Cell-Selective Targeting and Regulation The precision gene therapies being developed at Encoded are potentially capable of targeting specific cell types or levels of expression to address a range of disease mechanisms. Learn more
